Abbisko Cayman Reports Promising cGvHD Drug Results

Abbisko Cayman Limited (HK:2256) has released an update.

Abbisko Cayman Limited revealed encouraging preliminary results from its Phase II study of pimicotinib, a novel treatment for chronic Graft-versus-Host Disease (cGvHD), at the 66th ASH Annual Meeting. The study shows a promising 64% overall response rate in patients, suggesting pimicotinib’s potential as an effective therapy for cGvHD. These findings highlight the drug’s robust efficacy and tolerability, offering hope for patients with this challenging condition.

For further insights into HK:2256 stock, check out TipRanks’ Stock Analysis page.